Another Nextstellis Mention

An index analysis written by Claire Aitchison for Livewire Markets published earlier today. See below.

As I have said before Nextstellis is generating a lot of comment for MYX.

***********************************************************************************************

The IIR Pharma & Biotech Index increased slightly in March, up 1.3%. The index has performed strongly since the lows resulting from the pandemic, up 67.4% over the 12-months to 31 March 2021. This compares to the broader market (ASX All Ordinaries Accumulation Index) which was up 41.1%.
IIR Pharma & Biotech Index*

*The IIR Pharma & Biotech Index is a market capitalisation weighted index and currently includes 139 stocks across the Pharmaceutical, Biotech, Health Care Suppliers, Health Care and Equipment, Health Care Technology and Life Sciences GICs sectors. The index excludes the five largest companies in these sectors being ANN, COH, CSL, FPH and RMD. Source: Supplied.
Opthea Limited (ASX: OPT) fell out of the top 10 in March, with Mayne Pharma Group (ASX: MYX) moving into the top 10 after the share price increased 27.3% for the month. The share price was buoyed by the release of positive data regarding NEXTSTELLIS, a novel, investigational combined oral contraceptive. The positive momentum has continued in early April with the stock nearing its 52 week high. MSB continued to weaken, down 11.8% in March to be trading at $2.17 per share at March-end. This is down from the high of $5.70 per share in September 2020.

Over the 12-months to 31 March 2021, of the top 10 constituents in the index, IMU has been the best performer with the share price increasing 500%. TLX has been the second best performer, up 330.2%. SPL and PME have also performed strongly over the 12-month period, up 149.4% and 112.7%, respectively.